Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
RJR-2403: a nicotinic agonist with CNS selectivity II
Letermovir has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections
Smiles: CCCCCCCCCC1=CC=C(C=C1)OCCO
AMD 3465 works by antagonizing the HIV-1 entry co-receptor CXCR4
2-dihydrophthalazine hydrochloride
CF53 Size:Contact [email protected] for quotation RJR-2403: a nicotinic agonist withCF53 is a highly potent, selective and orally active inhibitor of BET protein, with a Ki of <1 nM, Kd of 2. 2 nM and an IC50 of 2 nM for BRD4 BD1. CF53 binds to both the BD1 and BD2 domains of BRD2, BRD3, BRD4, and BRDT BET proteins with high affinities, very selective over non BET bromodomain containing proteins. CF53 shows potent anti tumor activity both in vitro and in vivo. Product information CAS Number: 1808160 52 2 Molecular Weight: 443. 50